Amphion Innovations plc
Directors' Dealings
London and New York, 10 January 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 5 January 2018 it granted options over ordinary shares in the Company (“Options”) to certain of its directors as follows:
| Director | Amount | Strike Price |
Vesting |
| Richard Mansell-Jones | 563,000 | 1.94 pence | Over 1 year starting as of 1 August 2017 |
| Miroslaw Izienicki | 375,000 | 1.94 pence | Over 1 year starting as of 1 August 2017 |
All Options commence vesting backdated from 1 August 2017.
The strike price is based on the closing price on 4 January 2018, and the Options are exercisable on the date of vesting. Authority for the allotment of ordinary shares under the Share Option Scheme was approved as a part of the Company’s Annual General Meeting.
In addition to the above Options allocation, the Company has issued 799,562 ordinary shares in the Company (“New Ordinary Shares”), representing 0.38% of the enlarged issued share capital, to certain of its Board members (current and former) in payment of directors’ fees due them. The issue of Ordinary Shares is calculated based on the closing mid-market price for the five days leading up to the close on 4 January 2018. Following this issue the current directors’ shareholdings in the Company are as follows:
| Director | # of New Ordinary Shares | Total Shareholding |
Percentage of Voting Rights |
| Miroslaw Izienicki | 193,791 | 795,280 | 0.379% |
| Richard Mansell-Jones | 558,896 | 4,344,426 | 2.069% |
| Gerard Moufflet | 46,875 | 1,320,833 | 0.629% |
Admission of the 799,562 New Ordinary Shares, ranking pari passu with the existing ordinary shares, to trading on AIM is expected on 17 January 2018. Following the issue and allotment of the New Ordinary Shares, the total issued share capital of the Company will increase to 209,975,450 ordinary shares with each share holding one voting right. This figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information please contact
Amphion Innovations
Charlie Morgan
+1 212 210 6224
Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Ryan McCarthy (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Mark Treharne (Corporate Broking)
+44 (0)20 3861 6600
Walbrook PR
Paul McManus
+44 (0)20 7933 8780
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.
